Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

NCT01415752 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

373

Enrollment

NETWORK

Sponsor class

Conditions

Lymphoma
Mantle Cell Lymphoma

Interventions

BIOLOGICAL: rituximab
DRUG: Bendamustine
DRUG: bortezomib
DRUG: lenalidomide

Sponsor

Eastern Cooperative Oncology Group

Collaborators

[object Object]